Adamas Pharmaceuticals Profit Margin

Adamas Pharmaceuticals (ADMS) currently reports a profit margin of -71.11% as of September 2021. That compares with -89.12% in the prior-year period — up 20.2% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Adamas Pharmaceuticals's profit margin history and peer comparisons.

Adamas Pharmaceuticals's profit margin increased from -89.12% to -71.11% — a 20.2% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adamas Pharmaceuticals's profit margin of -71.11% is lower than the Healthcare sector average of 21.34%. That is roughly 433.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Adamas Pharmaceuticals's current -71.11% should be judged against Healthcare norms (sector average: 21.34%) and against ADMS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -71.11%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Adamas Pharmaceuticals, and consider following ADMS for alerts when major investors trade the stock.